Open Access

Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report

  • Authors:
    • Shuo‑Meng Xiao
    • Rui Xu
    • Xiao‑Li Tang
    • Zhi Ding
    • Ji‑Man Li
    • Xiang Zhou
  • View Affiliations

  • Published online on: June 11, 2018     https://doi.org/10.3892/ol.2018.8942
  • Pages: 2085-2090
  • Copyright: © Xiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric cancer is a common cancer of the gastrointestinal tract and the second most prevalent cause of cancer‑associated mortality globally. Gastric cancer‑associated mortality is increased in China compared with that in other countries. Key contributors to the poor prognosis of gastric cancer include late clinical presentation and genetic heterogeneity. Treatment based on the subtype of gastric cancer is important for effective therapy. The overexpression of the erb‑b2 receptor tyrosine kinase 2 (ERBB2) gene and protein is associated with gastric cancer in humans. Chemotherapy and targeted therapy may control tumor growth and recurrence, which is an important function of conversion surgery. The present study reported a patient diagnosed with gastric cancer with multiple abdominal cavity and retroperitoneal lymph node metastases. ERBB2 amplification and overexpression were identified in both case reports presented. The patients were treated with four cycles of oxaliplatin, capecitabine and trastuzumab. Computed tomography revealed the lymph node metastases decreased in size following treatment, and surgical resection was performed. The four cycles of oxaliplatin, capecitabine and trastuzumab were continued subsequent to surgical resection at the administered dose. No recurrence was observed for >1 year after surgery. Trastuzumab combined with oxaliplatin and capecitabine as a conversion therapy regime for ERBB2‑overexpressing advanced gastric adenocarcinoma increased the likelihood of successful surgical resection, and prolonged progression‑free survival.
View Figures
View References

Related Articles

Journal Cover

August-2018
Volume 16 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xiao SM, Xu R, Tang XL, Ding Z, Li JM and Zhou X: Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report. Oncol Lett 16: 2085-2090, 2018
APA
Xiao, S., Xu, R., Tang, X., Ding, Z., Li, J., & Zhou, X. (2018). Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report. Oncology Letters, 16, 2085-2090. https://doi.org/10.3892/ol.2018.8942
MLA
Xiao, S., Xu, R., Tang, X., Ding, Z., Li, J., Zhou, X."Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report". Oncology Letters 16.2 (2018): 2085-2090.
Chicago
Xiao, S., Xu, R., Tang, X., Ding, Z., Li, J., Zhou, X."Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report". Oncology Letters 16, no. 2 (2018): 2085-2090. https://doi.org/10.3892/ol.2018.8942